R&D channel feed

Eye­Bio tar­gets reg­is­tra­tional tri­al af­ter ear­ly suc­cess of Wnt ag­o­nist in reti­nal dis­eases

Last year

G1 Ther­a­peu­tic­s' stock sinks near­ly 40% on PhI­II read­out de­lay

Last year

Ot­su­ka’s fixed-dose com­bo dis­ap­points in PhI­II tri­al for Alzheimer’s ag­i­ta­tion

Last year

Roche walks away from Re­pare sol­id tu­mor deal just weeks af­ter $40M mile­stone pay­out

Last year
Deals

KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

Last year

Lari­mar Ther­a­peu­tics shares key bio­mark­er da­ta, aims for ac­cel­er­at­ed ap­proval for Friedre­ich’s atax­ia drug

Last year

In­fec­tious dis­ease biotech halts late-stage tri­al due to sub­par ef­fi­ca­cy, shares plum­met 70%

Last year

A sweep­ing form of search-and-re­place edit­ing has come for mR­NA

Last year
In Focus

CSL shares down 5% af­ter post-heart at­tack drug dis­ap­points in late-stage test

Last year

Cor­rec­tion: Iambic says new AI mod­el bests Al­phaFold as pro­tein mod­els rock­et ahead

Last year
AI

CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

Last year
Pharma
Cell/Gene Tx

Syn­log­ic reach­es end of the road for syn­thet­ic bi­ol­o­gy quest af­ter piv­otal da­ta dis­ap­point

Last year
People

Madri­gal re­ports new safe­ty da­ta for NASH can­di­date resme­tirom weeks ahead of PDU­FA date

Last year

Re­genxbio to seek ac­cel­er­at­ed ap­proval of Hunter syn­drome gene ther­a­py us­ing bio­mark­er da­ta

Last year
Cell/Gene Tx

An eye-drop ver­sion of Krys­tal Biotech's skin gene ther­a­py helped re­store vi­sion of boy with rare dis­ease

Last year
Cell/Gene Tx

Gilead stops last PhI­II of CD47 drug, cit­ing FDA hold, high­er risk of death in treat­ment arm

Last year

De­nali touts more bio­mark­er da­ta with ac­cel­er­at­ed ap­proval in mind

Last year

In a snap­shot of its rare dis­ease da­ta, Ul­tragenyx boosts case for new sur­ro­gate bio­mark­er

Last year
Cell/Gene Tx

Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Last year
Pharma

Up­dat­ed: Lil­ly re­ports mid-stage win for tirzepatide in fat­ty liv­er dis­ease MASH

Last year

GSK de­tails Blenrep’s PhI­II com­bo win as it hopes to stage a turn­around in mul­ti­ple myelo­ma

Last year

J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

Last year

Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

Last year

Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Last year
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times